This project represents a first systematic, prospective, single-arm cohort study of a safe
and effective dosing regimen of an orally administered cannabis oil formulation in a cancer
subject population with poorly controlled pain.
Phase:
Phase 2
Details
Lead Sponsor:
Aurora Cannabis Inc MedReleaf
Collaborators:
Hamilton Health Sciences Corporation Ontario Clinical Oncology Group (OCOG)